Moderna

Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna

Retrieved on: 
Thursday, April 4, 2024
Plaintiff, Patent, District court, COVID-19, CFBV, Arbutus, Sale, Messenger, Moderna, Virology, Interim, Court, LNP

8,058,069, 8,492,359, 8,822,668, 9,364,435, 9,504,651, and 11,141,378 in the manufacture and sale of MRNA-1273, Moderna’s vaccine for COVID-19.

Key Points: 
  • 8,058,069, 8,492,359, 8,822,668, 9,364,435, 9,504,651, and 11,141,378 in the manufacture and sale of MRNA-1273, Moderna’s vaccine for COVID-19.
  • The following summarizes the Court’s Opinion:
    The Court agreed with Plaintiffs’ position that the claimed molar percentage (mol.
  • %) ranges can be met by any particle and is not limited to “finished” particles that are not subjected to further process steps.
  • “We are pleased with how the Court construed the disputed claim terms,” said Michael J. McElhaugh, Interim President and Chief Executive Officer of Arbutus Biopharma.

Blackstone Life Sciences Announces Collaboration to Support Moderna’s Influenza Program

Retrieved on: 
Wednesday, March 27, 2024
Professional Services, Health, Finance, Research, Science, Pharmaceutical, Biotechnology, Moderna, Messenger, Patient, BX, MRNA, Vaccine

Blackstone (NYSE:BX) announced today a new collaboration with Moderna, Inc. (NASDAQ: MRNA, “Moderna”) through a development and commercialization funding agreement where funds managed by Blackstone Life Sciences (“Blackstone”) will provide up to $750 million to fund Moderna’s influenza (“flu”) program.

Key Points: 
  • Blackstone (NYSE:BX) announced today a new collaboration with Moderna, Inc. (NASDAQ: MRNA, “Moderna”) through a development and commercialization funding agreement where funds managed by Blackstone Life Sciences (“Blackstone”) will provide up to $750 million to fund Moderna’s influenza (“flu”) program.
  • This landmark collaboration is another example of our long-standing strategy to partner with the world’s leading life science companies to advance their critical path vaccines, medicines and medical technologies to patients,” said Nicholas Galakatos, Ph.D., Global Head of Blackstone Life Sciences.
  • Achieving this ambition requires substantial investment in late-stage studies and we are excited to welcome Blackstone and their innovative financing model.”
    This new collaboration continues Blackstone Life Sciences’ work and support for many of the world’s leading and most innovative biopharmaceutical and medical technology companies.
  • Blackstone seeks to provide customized financing solutions for companies across therapeutic areas to support mission critical scientific innovation and advance important products to patients.

Global H3N2 infection Drug Pipeline Landscape Report 2024: Insights on 15+ Companies and 20+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 27, 2024
Health, Infectious Diseases, Therapy, Acquisition, Pfizer, SARS-CoV-2, AVC, News, Glycoprotein, Moderna, NTD, RBD, FC, Discovery, COVID-19, Clinical trial, NDA, N-terminus, Immune system, Pharmaceutical industry

This report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in H3N2 infection pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in H3N2 infection pipeline landscape.
  • A detailed picture of the H3N2 infection pipeline landscape is provided which includes the disease overview and H3N2 infection treatment guidelines.
  • The assessment part of the report embraces, in depth H3N2 infection commercial assessment and clinical assessment of the pipeline products under development.
  • The companies which have their H3N2 infection drug candidates in the most advanced stage, i.e.

ReNAgade Therapeutics Appoints Joe Bolen, Ph.D., Chief Science Innovation Officer

Retrieved on: 
Tuesday, February 27, 2024
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, Bangladesh Technical Education Board, Takeda Pharmaceutical Company, MPM, Schering-Plough, Science Publishing Group, Hoechst AG, Research and development, NIH, Moderna, PureTech Health, Drug development, Bristol Myers Squibb, Doctor of Philosophy, Renegade, University, Partner, RNA, Therapy, Patient, Protein, Takeda Oncology, Development, Immune system, Pharmaceutical industry

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Joe Bolen, Ph.D., an Executive Partner at MPM BioImpact, former Chief Scientific Officer at PureTech Health and former President of Research and Development of Moderna Therapeutics, will serve as the company’s first Chief Science Innovation Officer.

Key Points: 
  • ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Joe Bolen, Ph.D., an Executive Partner at MPM BioImpact, former Chief Scientific Officer at PureTech Health and former President of Research and Development of Moderna Therapeutics, will serve as the company’s first Chief Science Innovation Officer.
  • “Joe is a pioneering scientist and drug development expert who brings to ReNAgade more than four decades of experience in oncology and immunology,” said Amit D. Munshi, Chief Executive Officer of ReNAgade.
  • Before joining PureTech, he oversaw all aspects of research and development for Moderna Therapeutics as President of Research & Development and Chief Scientific Officer.
  • Previously, he was Chief Scientific Officer at Millennium Pharmaceuticals and Global Head of Oncology Research at Takeda Pharmaceutical Company.

Robert S. Langer, Co-Founder of Moderna, Joins Lindus Health's Advisory Board

Retrieved on: 
Thursday, January 25, 2024
Advisory board, Biotechnology, ChromeOS, MIT, Patient, Clinical trial, History, Moderna, Professor, Pharmaceutical industry

Dr. Langer has received more than 220 major awards, has authored over 1,570 articles, and has more than 1,400 patents issued and pending globally.

Key Points: 
  • Dr. Langer has received more than 220 major awards, has authored over 1,570 articles, and has more than 1,400 patents issued and pending globally.
  • These patents have been licensed or sublicensed to over 400 companies spanning pharmaceuticals, chemicals, biotechnology, and medical devices.
  • He is the most cited engineer in history (h-index 319 with more than 412,500 citations according to Google Scholar).
  • Michael Young, co-founder of Lindus Health said: "We are incredibly humbled to welcome Dr. Langer to our advisory board.

Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023

Retrieved on: 
Tuesday, November 14, 2023
Pfizer, Antigen, Associate professor, Immune system, GeoVax, Animal, Immunodeficiency, Biotechnology, Protein, Capsid, MVA, Georgia State University, Patient, Vaccine, Immunization, Dihydrolipoyllysine-residue (2-methylpropanoyl)transferase, Infection, Messenger, COVID-19, Monoclonal antibody, Chronic lymphocytic leukemia, Death, Antibody, Alpha, Doctor of Philosophy, Protein structure, SARS-CoV-2, Cancer, CLL, Inflammation, Pharmaceutical industry, Moderna, Boston, Omicron

ATLANTA, GA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the presentation of preclinical vaccine efficacy data for GEO-CM02, a multi-antigen investigational SARS-CoV-2 vaccine. The data were presented during the Vaccines Summit 2023 conference, being held in Boston, MA on November 13-15, 2023. The presentation, titled “MVA-vectored multi-antigen COVID-19 vaccines induce protective immunity against SARS-CoV-2 variants spanning Alpha to Omicron in preclinical animal models,” was delivered by Mukesh Kumar, PhD, Associate Professor, Department of Biology, Georgia State University.

Key Points: 
  • The data were presented during the Vaccines Summit 2023 conference, being held in Boston, MA on November 13-15, 2023.
  • To address this limitation, GeoVax is currently evaluating its dual antigen COVID-19 vaccine, GEO-CM04S1 in three Phase 2 clinical trials.
  • Data highlights from the Vaccine Summit 2023 presentation are as follows:
    The GEO-CM02 vaccine induced immune responses that were efficacious against the original Wuhan strain and BA.1 Omicron variant with a single dose.
  • As a booster vaccine for healthy patients who have previously received the Pfizer or Moderna mRNA vaccine.

Immatics Announces Third Quarter 2023 Financial Results and Business Update

Retrieved on: 
Tuesday, November 14, 2023
Senior, Entrepreneurship, CRS, Peptide, Regenerative Medicine Advanced Therapy, Patient, Triple-negative breast cancer, Cell, Research, Pharmacology, Therapy, Conference, ORR, Neurotoxicity, Infrared spectroscopy correlation table, Cytokine release syndrome, Uveal melanoma, Bristol Myers Squibb, Safety, Head, Cancer, Administration, CD4, PRAME, Uterine cancer, Lung cancer, Melanoma, Ovarian cancer, Half-life, Development, SAB, BRAF, CD8, MAGEA4, Cytopenia, TCR, Protein, FDA, DLT, Messenger, Cmax, Toxic epidermal necrolysis, Sarcoma, CMC, Neoplasm, Vaccine, Medical imaging, Pharmaceutical industry, Cryptocurrency, Fine chemical, Drug, Moderna, NSCLC

“Immatics has had a strong quarter and made steady progress both in terms of the advancement of our clinical programs and in business development.

Key Points: 
  • “Immatics has had a strong quarter and made steady progress both in terms of the advancement of our clinical programs and in business development.
  • An update on the clinical development plan is expected in the first quarter of 2024.
  • An update on the clinical development plan is expected in the first quarter of 2024.
  • On September 11, Immatics announced a strategic multi-platform collaboration with Moderna, combining Immatics’ target and TCR platforms with Moderna’s cutting-edge mRNA technology.

Generation Bio Reports Business Highlights and Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023
Cytokine, DNA, Spleen, D, Haemophilia, Gene, Therapeutic index, Liver, Tissue, Mouse, Cell, Research, ESGCT, G&A, Messenger, LNP, Innate lymphoid cell, NHP, Moderna, R, Congress, RNA, Vaccine

CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and third quarter 2023 financial results.

Key Points: 
  • (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and third quarter 2023 financial results.
  • “The recent advances in our immune-quiet DNA (iqDNA) and cell-targeted lipid nanoparticle (ctLNP) platforms represent two breakthroughs in the field of genetic medicine,” said Geoff McDonough, chief executive officer of Generation Bio.
  • R&D Expenses: Research and development (R&D) expenses were $21.9 million for the quarter ended September 30, 2023, compared to $21.2 million for the quarter ended September 30, 2022.
  • G&A Expenses: General and administrative (G&A) expenses were $11.6 million for the quarter ended September 30, 2023, compared to $11.5 million for the quarter ended September 30, 2022.

Atropos Health Forms Life Science Advisory Board, Increasing Commitment to Accelerated Drug Development and Clinical Trial Diversity and Inclusion

Retrieved on: 
Thursday, November 30, 2023
Biotechnology, Technology, Professional Services, Health, Pharmaceutical, DEI (Diversity, Equity and Inclusion), Research, Data Analytics, Artificial Intelligence, Science, Clinical Trials, Medicine, Translation, Real, Real world data, Organization, Entrepreneurship, Synthetic media, Acceleration, Chat, Drug discovery, PwC, Drug development, Pharmaceutical industry, Moderna, Novartis, AI

“I firmly believe that 2024 will be a revolutionary year in drug discovery and the acceleration of early drug development following the heels of innovation in AI,” said Dr. Brigham Hyde, Co-Founder and CEO Atropos Health.

Key Points: 
  • “I firmly believe that 2024 will be a revolutionary year in drug discovery and the acceleration of early drug development following the heels of innovation in AI,” said Dr. Brigham Hyde, Co-Founder and CEO Atropos Health.
  • They join Dr. Sean Khozin of Braven and Phyusion and Gerry McDougall former Senior Healthcare Consulting Partner at PwC.
  • “By dismantling barriers to accessing data and fostering an exchange of observational insights, Atropos Health is redefining life science clinical trials’ research and delivery,” said Salami.
  • “By democratizing access to essential data, Atropos Health is putting its insight potential into everyone’s hands and leading a powerful paradigm shift.”

First In Vivo CAR-M Lead Candidate Nominated Under Carisma-Moderna Collaboration

Retrieved on: 
Thursday, December 14, 2023
Entrepreneurship, Therapy, LNP, IND, Doctor of Pharmacy, Northwest Biotherapeutics, Patient, Myelocyte, Messenger, CARM, SITC, Doctor of Philosophy, Cancer, RNA, Pharmaceutical industry, Moderna, Mitsubishi Carisma

PHILADELPHIA, Dec. 14, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the nomination of its first lead candidate under the collaboration with Moderna, Inc. (Nasdaq: MRNA). This first lead candidate will target an antigen present on a solid tumor with significant unmet medical need. This strategic collaboration brings together Carisma's chimeric antigen receptor macrophage (CAR-M) platform with Moderna's messenger RNA (mRNA) and lipid nanoparticle (LNP) technologies to generate and develop in vivo CAR-M therapeutics for oncology.

Key Points: 
  • This first lead candidate will target an antigen present on a solid tumor with significant unmet medical need.
  • This strategic collaboration brings together Carisma's chimeric antigen receptor macrophage (CAR-M) platform with Moderna's messenger RNA (mRNA) and lipid nanoparticle (LNP) technologies to generate and develop in vivo CAR-M therapeutics for oncology.
  • "The delivery of this first candidate demonstrates our ability to create novel in vivo CAR therapies that can be advanced toward the clinic.
  • We look forward to completing IND-enabling studies with the lead candidate and are excited about the prospect of bringing this therapy forward for patients with advanced solid tumors together with Moderna."